Home LiteratureArticle Details
PMID: 19837059 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Immunotherapy of cancer.

European journal of pharmacology ·Vol. 625 ·No. 1-3 ·2009-12-25 ·Pages 41-54

Borghaei H, Smith MR, Campbell KS

Abstract

Major advances have been made in the field of immunology in the past two decades. A better understanding of the molecular and cellular mechanisms controlling the immune system has opened the door to many innovative and promising new cancer therapies that manipulate the immune response. For instance, toll-like receptor agonists have been shown to boost immune responses toward tumors. Also, a wide array of cell-based immunotherapies utilizing T cells, NK cells, and dendritic cells have been established. Furthermore, a rapidly expanding repertoire of monoclonal antibodies is being developed to treat tumors, and many of the available antibodies have demonstrated impressive clinical responses. Here, we examine some of these immunotherapeutic approaches currently in use or testing to treat cancer, and we examine available evidence with regards to mechanism and efficacy of these treatments.

MeSH Terms
Animals Antibodies, Monoclonal/immunology,therapeutic use Dendritic Cells/immunology Humans Immunotherapy/methods Killer Cells, Natural/immunology Neoplasms/immunology,radiotherapy,therapy Radioimmunotherapy/methods T-Lymphocytes/immunology Toll-Like Receptors/agonists
Chemicals
Antibodies, Monoclonal Toll-Like Receptors
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Borghaei Hossein
Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. hossein.borghaei@fccc.edu
Smith Mitchell R
Campbell Kerry S
References (185)
185 references, click to expand
  1. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity.
    Annu Rev Immunol. 2002;20:217-51 PMID: 11861603
  2. Targeted therapies for the treatment of cancer.
    Am J Surg. 2003 Sep;186(3):264-8 PMID: 12946830
  3. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
    J Clin Oncol. 1996 Mar;14(3):737-44 PMID: 8622019
  4. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
    Br J Haematol. 2008 Jan;140(1):36-45 PMID: 17995965
  5. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
    Br J Haematol. 2007 Feb;136(3):439-47 PMID: 17233846
  6. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
    Blood. 2002 Feb 1;99(3):1038-43 PMID: 11807010
  7. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
    Cancer Res. 2006 Mar 1;66(5):2520-6 PMID: 16510567
  8. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
    Cancer Res. 1995 Jun 15;55(12):2627-34 PMID: 7540106
  9. Highly efficient selection of phage antibodies mediated by display of antigen as Lpp-OmpA' fusions on live bacteria.
    J Mol Biol. 2000 Aug 25;301(4):893-904 PMID: 10966794
  10. Functional CD32 molecules on human NK cells.
    Leuk Lymphoma. 1999 Sep;35(1-2):47-56 PMID: 10512162
  11. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Nat Med. 2000 Apr;6(4):443-6 PMID: 10742152
  12. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
    Blood. 2000 Jun 15;95(12):3900-8 PMID: 10845926
  13. Continuous cultures of fused cells secreting antibody of predefined specificity.
    Nature. 1975 Aug 7;256(5517):495-7 PMID: 1172191
  14. Cancer immunotherapy by dendritic cells.
    Immunity. 2008 Sep 19;29(3):372-83 PMID: 18799145
  15. Use of natural killer cells in hematopoetic stem cell transplantation.
    Bone Marrow Transplant. 2005 Apr;35(7):637-43 PMID: 15654351
  16. Clinical trials of Herceptin(trastuzumab).
    Eur J Cancer. 2001 Jan;37 Suppl 1:S18-24 PMID: 11167087
  17. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment.
    J Biol Chem. 1998 Jan 2;273(1):344-8 PMID: 9417086
  18. Autoantibody signatures in prostate cancer.
    N Engl J Med. 2005 Sep 22;353(12):1224-35 PMID: 16177248
  19. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.
    J Clin Oncol. 2009 Mar 20;27(9):1470-6 PMID: 19224853
  20. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias.
    Blood. 2005 Mar 15;105(6):2594-600 PMID: 15536148
  21. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
    Cancer Cell. 2006 Nov;10(5):389-99 PMID: 17097561
  22. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
    J Clin Oncol. 2004 Oct 15;22(20):4095-102 PMID: 15353540
  23. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    N Engl J Med. 2004 Jun 3;350(23):2335-42 PMID: 15175435
  24. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    J Clin Oncol. 2005 Aug 1;23(22):5027-33 PMID: 15955905
  25. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
    J Clin Oncol. 2004 Apr 1;22(7):1201-8 PMID: 14993230
  26. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
    Blood. 2008 Jun 1;111(11):5350-8 PMID: 18292288
  27. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
    N Engl J Med. 2001 Jul 26;345(4):241-7 PMID: 11474661
  28. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.
    Blood. 2003 Feb 1;101(3):1071-9 PMID: 12393727
  29. CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
    Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5556s-5563s PMID: 17875789
  30. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
    J Clin Oncol. 2002 Jan 1;20(1):205-13 PMID: 11773171
  31. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
    J Clin Oncol. 2007 Jul 1;25(19):2764-9 PMID: 17515574
  32. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.
    Blood. 2003 Aug 1;102(3):814-9 PMID: 12689936
  33. Antibody-dependent cellular cytotoxicity in HIV infections.
    FASEB J. 1996 Feb;10(2):258-66 PMID: 8641559
  34. Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics.
    J Immunol Methods. 2001 Feb 1;248(1-2):31-45 PMID: 11223067
  35. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Clin Cancer Res. 2005 Jul 15;11(14):5215-22 PMID: 16033839
  36. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia.
    Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55 PMID: 17671129
  37. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.
    Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 PMID: 16864058
  38. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.
    J Clin Oncol. 2005 Jul 1;23(19):4390-8 PMID: 15994148
  39. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
    J Clin Oncol. 2003 Nov 1;21(21):3940-7 PMID: 12975461
  40. Immune complex-mediated antigen presentation induces tumor immunity.
    J Clin Invest. 2002 Jul;110(1):71-9 PMID: 12093890
  41. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
    J Clin Oncol. 2005 May 20;23(15):3502-8 PMID: 15908660
  42. Hepatitis B virus, the vaccine, and the control of primary cancer of the liver.
    Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7121-5 PMID: 9207053
  43. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
    Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512-7 PMID: 18040043
  44. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
    J Clin Oncol. 2005 Aug 20;23(24):5696-704 PMID: 16110029
  45. 131I-tositumomab therapy as initial treatment for follicular lymphoma.
    N Engl J Med. 2005 Feb 3;352(5):441-9 PMID: 15689582
  46. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
    J Clin Oncol. 2005 Oct 20;23(30):7565-73 PMID: 16186600
  47. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.
    Eur J Pharmacol. 2007 Jun 1;563(1-3):1-17 PMID: 17383632
  48. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
    Int J Cancer. 2006 Jul 15;119(2):317-27 PMID: 16482562
  49. CD4 cells can be more efficient at tumor rejection than CD8 cells.
    Blood. 2007 Jun 15;109(12):5346-54 PMID: 17327412
  50. Toll-like receptors and cancer.
    Nat Rev Cancer. 2009 Jan;9(1):57-63 PMID: 19052556
  51. Clathrin-independent endocytosis of ubiquitinated cargos.
    Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2760-5 PMID: 15701692
  52. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
    Blood. 2002 Feb 1;99(3):754-8 PMID: 11806974
  53. Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer.
    Thyroid. 2007 Jan;17(1):53-8 PMID: 17274750
  54. The EGFR as a target for anticancer therapy--focus on cetuximab.
    Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22 PMID: 11597400
  55. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor.
    Blood. 2002 Nov 15;100(10):3825-7 PMID: 12393440
  56. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2.
    Br J Haematol. 2001 May;113(2):455-60 PMID: 11380416
  57. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
    Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23 PMID: 11255078
  58. Combining radiation and immunotherapy for synergistic antitumor therapy.
    Curr Opin Mol Ther. 2009 Feb;11(1):37-42 PMID: 19169958
  59. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
    J Clin Oncol. 2008 Nov 10;26(32):5275-83 PMID: 18838703
  60. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival.
    Blood. 2006 Jun 15;107(12):4807-16 PMID: 16484589
  61. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
    J Clin Oncol. 2005 Feb 1;23(4):712-9 PMID: 15613695
  62. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words.
    Q J Nucl Med Mol Imaging. 2004 Dec;48(4):251-7 PMID: 15640788
  63. Vaccines against cervical cancer.
    Curr Opin Oncol. 2008 Sep;20(5):570-4 PMID: 19106663
  64. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
    J Clin Oncol. 2009 Apr 1;27(10):1607-14 PMID: 19255334
  65. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
    Blood. 2008 Aug 15;112(4):1175-83 PMID: 18523152
  66. Stability engineering of antibody single-chain Fv fragments.
    J Mol Biol. 2001 Feb 2;305(5):989-1010 PMID: 11162109
  67. Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells.
    J Mol Med (Berl). 2002 Apr;80(4):248-57 PMID: 11976734
  68. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
    Oncogene. 2007 May 28;26(25):3614-28 PMID: 17530015
  69. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
    J Clin Oncol. 2005 Feb 1;23(4):741-50 PMID: 15613700
  70. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
    N Engl J Med. 2007 Dec 27;357(26):2666-76 PMID: 18160686
  71. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.
    Nat Biotechnol. 1999 Feb;17(2):176-80 PMID: 10052355
  72. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
    J Immunol. 2002 Aug 15;169(4):1792-800 PMID: 12165501
  73. Monoclonal antibody therapy for cancer.
    Annu Rev Med. 2003;54:343-69 PMID: 12525678
  74. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature.
    Blood. 2007 Jul 15;110(2):578-86 PMID: 17392508
  75. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
    J Clin Oncol. 2008 Jan 1;26(1):90-5 PMID: 18025438
  76. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
    Blood. 2009 Jan 15;113(3):726-32 PMID: 18945962
  77. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Clin Cancer Res. 1999 Sep;5(9):2392-8 PMID: 10499609
  78. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.
    J Clin Oncol. 1998 Aug;16(8):2752-60 PMID: 9704728
  79. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
    J Clin Oncol. 2006 Jul 1;24(19):3121-7 PMID: 16754935
  80. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.
    Blood. 1994 Jan 15;83(2):435-45 PMID: 7506951
  81. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma.
    Clin Lymphoma. 2000 Jun;1(1):57-61 PMID: 11707814
  82. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
    Science. 2002 Mar 15;295(5562):2097-100 PMID: 11896281
  83. Human immune response to monoclonal antibodies.
    J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):42-52 PMID: 8110730
  84. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion.
    Eur J Immunol. 1976 Jul;6(7):511-9 PMID: 825377
  85. Tunable antibodies.
    Nat Biotechnol. 2005 May;23(5):556-7 PMID: 15877072
  86. Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
    Nat Rev Drug Discov. 2003 Jan;2(1):52-62 PMID: 12509759
  87. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
    J Clin Oncol. 2007 Apr 10;25(11):1396-402 PMID: 17312330
  88. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
    J Clin Oncol. 1998 Aug;16(8):2659-71 PMID: 9704716
  89. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
    J Clin Oncol. 2001 May 15;19(10):2722-30 PMID: 11352965
  90. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity.
    Blood. 2009 May 28;113(22):5628-34 PMID: 19329778
  91. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.
    Ann Oncol. 2007 Jul;18(7):1216-23 PMID: 17470451
  92. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
    J Clin Oncol. 2005 Aug 1;23(22):5044-51 PMID: 15955901
  93. Identification of the CD32/FcgammaRIIc-Q13/STP13 polymorphism using an allele-specific restriction enzyme digestion assay.
    J Immunol Methods. 2001 Dec 1;258(1-2):85-95 PMID: 11684126
  94. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
    J Clin Oncol. 2006 Aug 20;24(24):3880-6 PMID: 16864854
  95. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    N Engl J Med. 2002 Jan 24;346(4):235-42 PMID: 11807147
  96. The B7 family revisited.
    Annu Rev Immunol. 2005;23:515-48 PMID: 15771580
  97. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
    J Immunol. 2008 May 1;180(9):6392-401 PMID: 18424763
  98. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
    J Clin Oncol. 2000 Apr;18(8):1622-36 PMID: 10764422
  99. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Clin Cancer Res. 2006 Dec 1;12(23):7046-53 PMID: 17145827
  100. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy.
    Leukemia. 2003 Aug;17(8):1658-64 PMID: 12886256
  101. Potential target antigens for immunotherapy identified by serological expression cloning (SEREX).
    Methods Mol Biol. 2007;360:319-26 PMID: 17172736
  102. The biology of vascular endothelial growth factor.
    Endocr Rev. 1997 Feb;18(1):4-25 PMID: 9034784
  103. Ex vivo expansion of natural killer cells for clinical applications.
    Cytotherapy. 2004;6(1):15-22 PMID: 14985163
  104. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
    J Clin Oncol. 2007 Mar 1;25(7):876-83 PMID: 17327609
  105. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding.
    J Immunol. 2002 Oct 15;169(8):4098-102 PMID: 12370336
  106. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays.
    Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17494-9 PMID: 17954908
  107. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.
    Clin Orthop Relat Res. 1991 Jan;(262):3-11 PMID: 1984929
  108. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
    J Clin Oncol. 2001 Jul 1;19(13):3234-43 PMID: 11432891
  109. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
    Lancet Oncol. 2006 May;7(5):379-91 PMID: 16648042
  110. Human diversity in killer cell inhibitory receptor genes.
    Immunity. 1997 Dec;7(6):753-63 PMID: 9430221
  111. Relationships between EGFR signaling-competent and endocytosis-competent membrane microdomains.
    Mol Biol Cell. 2005 Jun;16(6):2704-18 PMID: 15772153
  112. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
    Biol Blood Marrow Transplant. 2006 Aug;12(8):828-36 PMID: 16864053
  113. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
    Curr Opin Investig Drugs. 2005 Jun;6(6):582-91 PMID: 15988909
  114. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    J Clin Oncol. 2002 Aug 1;20(15):3262-9 PMID: 12149300
  115. Combining computational and experimental screening for rapid optimization of protein properties.
    Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):15926-31 PMID: 12446841
  116. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.
    Blood. 2005 Feb 15;105(4):1417-23 PMID: 15494430
  117. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
    Oncogene. 2007 May 28;26(25):3629-36 PMID: 17530016
  118. The therapeutic potential of 4-1BB (CD137) in cancer.
    Curr Cancer Drug Targets. 2005 Aug;5(5):357-63 PMID: 16101383
  119. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.
    Melanoma Res. 2003 Oct;13(5):521-30 PMID: 14512794
  120. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
    Br J Haematol. 2001 Sep;114(4):800-9 PMID: 11564066
  121. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
    Cancer Immun. 2009 Apr 02;9:3 PMID: 19338264
  122. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
    Cancer Immunol Immunother. 2005 Apr;54(4):307-14 PMID: 15599732
  123. Human NK cell education by inhibitory receptors for MHC class I.
    Immunity. 2006 Aug;25(2):331-42 PMID: 16901727
  124. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
    J Clin Oncol. 2005 Oct 1;23(28):7135-42 PMID: 16192597
  125. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.
    Br J Haematol. 2002 Jun;117(4):828-34 PMID: 12060117
  126. Use of tumour-responsive T cells as cancer treatment.
    Lancet. 2009 Feb 21;373(9664):673-83 PMID: 19231634
  127. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
    Oncologist. 2008 Feb;13(2):167-74 PMID: 18305062
  128. Rituximab: an insider's historical perspective.
    Semin Oncol. 2000 Dec;27(6 Suppl 12):9-16 PMID: 11226006
  129. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
    Cell. 1994 Oct 21;79(2):315-28 PMID: 7525077
  130. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
    Clin Cancer Res. 2009 Apr 15;15(8):2808-17 PMID: 19351768
  131. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.
    Blood. 2008 Feb 15;111(4):1848-54 PMID: 18079362
  132. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.
    Nat Med. 1997 Jun;3(6):682-5 PMID: 9176498
  133. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting.
    J Nucl Med. 2008 Jan;49(1):158-63 PMID: 18077530
  134. Functional analysis of TRAIL receptors using monoclonal antibodies.
    J Immunol. 1999 Mar 1;162(5):2597-605 PMID: 10072501
  135. CD20-mediated apoptosis: signalling through lipid rafts.
    Immunology. 2002 Oct;107(2):176-82 PMID: 12383196
  136. Overview of antibody phage-display technology and its applications.
    Methods Mol Biol. 2002;178:1-37 PMID: 11968478
  137. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
    Cancer Res. 1997 Oct 15;57(20):4593-9 PMID: 9377574
  138. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.
    J Cell Biol. 1993 Jun;121(5):1121-32 PMID: 7684739
  139. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.
    Cancer Metastasis Rev. 2005 Dec;24(4):487-99 PMID: 16408158
  140. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Clin Cancer Res. 2004 Aug 15;10(16):5327-34 PMID: 15328168
  141. The epidermal growth factor receptor as a target for colorectal cancer therapy.
    Semin Oncol. 2005 Feb;32(1):52-60 PMID: 15726506
  142. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma.
    Blood. 2004 Oct 15;104(8):2269-71 PMID: 15166030
  143. Behavior of immune players in the tumor microenvironment.
    Curr Opin Oncol. 2009 Jan;21(1):53-9 PMID: 19125019
  144. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
    J Nucl Med. 2007 Nov;48(11):1767-76 PMID: 17942813
  145. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
    J Clin Invest. 2002 Mar;109(5):651-9 PMID: 11877473
  146. Cancer regression in patients after transfer of genetically engineered lymphocytes.
    Science. 2006 Oct 6;314(5796):126-9 PMID: 16946036
  147. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells.
    Science. 1983 Aug 26;221(4613):865-7 PMID: 6879183
  148. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
    J Clin Oncol. 1998 Aug;16(8):2825-33 PMID: 9704735
  149. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
    Blood. 2005 Apr 15;105(8):3051-7 PMID: 15632206
  150. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    N Engl J Med. 2004 Jul 22;351(4):337-45 PMID: 15269313
  151. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    N Engl J Med. 2001 Mar 15;344(11):783-92 PMID: 11248153
  152. Natural born killers: NK cells drafted into the cancer fight.
    J Natl Cancer Inst. 2004 May 5;96(9):651-3 PMID: 15126597
  153. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.
    Hum Immunol. 2006 Mar;67(3):188-95 PMID: 16698441
  154. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma.
    Acta Oncol. 1998;37(3):285-9 PMID: 9677101
  155. Checkpoint blockade in cancer immunotherapy.
    Adv Immunol. 2006;90:297-339 PMID: 16730267
  156. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
    Blood. 1996 Aug 15;88(4):1188-97 PMID: 8695836
  157. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
    Blood. 2005 Jun 15;105(12):4878-84 PMID: 15731175
  158. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.
    Blood. 2003 Feb 1;101(3):949-54 PMID: 12393572
  159. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
    J Clin Oncol. 2006 Sep 1;24(25):4143-9 PMID: 16896003
  160. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
    Blood. 2006 Oct 15;108(8):2648-54 PMID: 16825493
  161. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer.
    Cancer Immunol Immunother. 2003 May;52(5):328-37 PMID: 12700948
  162. gammadelta T lymphocytes-selectable cells within the innate system?
    J Clin Immunol. 2007 Mar;27(2):133-44 PMID: 17333410
  163. CpG oligodeoxynucleotides as immunotherapy in cancer.
    Update Cancer Ther. 2008 Mar;3(1):27-32 PMID: 19255607
  164. CD4+ T-regulatory cells: toward therapy for human diseases.
    Immunol Rev. 2008 Jun;223:391-421 PMID: 18613849
  165. Dendritic-cell- and peptide-based vaccination strategies for glioma.
    Neurosurg Rev. 2009 Jul;32(3):265-73; discussion 273 PMID: 19214609
  166. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.
    Blood. 2008 Feb 1;111(3):1094-100 PMID: 18003886
  167. Determinants of antileukemia effects of allogeneic NK cells.
    J Immunol. 2004 Jan 1;172(1):644-50 PMID: 14688377
  168. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation.
    Blood. 2009 Apr 16;113(16):3875-84 PMID: 19179302
  169. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.
    Blood. 2007 Jun 1;109(11):5058-61 PMID: 17317850
  170. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
    Cancer Res. 2000 Dec 15;60(24):7170-6 PMID: 11156427
  171. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
    Br J Haematol. 2004 Dec;127(5):519-30 PMID: 15566355
  172. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade.
    EMBO J. 1996 Sep 16;15(18):4919-27 PMID: 8890165
  173. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
    J Clin Oncol. 2005 Feb 1;23(4):792-9 PMID: 15681523
  174. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
    Anticancer Res. 1999 Sep-Oct;19(5B):4203-14 PMID: 10628376
  175. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
    Blood. 2001 Dec 1;98(12):3383-9 PMID: 11719378
  176. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.
    Blood. 2003 Feb 1;101(3):1045-52 PMID: 12393541
  177. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
    N Engl J Med. 2006 Feb 9;354(6):567-78 PMID: 16467544
  178. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
    N Engl J Med. 2005 Oct 20;353(16):1673-84 PMID: 16236738
  179. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Clin Cancer Res. 2004 Apr 15;10(8):2868-78 PMID: 15102696
  180. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
    J Clin Oncol. 1999 Sep;17(9):2639-48 PMID: 10561337
  181. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.
    Haematologica. 2007 Aug;92(8):1127-30 PMID: 17650444
  182. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
    Anticancer Res. 2006 Mar-Apr;26(2A):1113-34 PMID: 16619514
  183. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
    Lancet. 2009 May 2;373(9674):1525-31 PMID: 19410716
  184. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.
    J Clin Oncol. 2012 Sep 1;30(25):3119-26 PMID: 22851557
  185. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts.
    Mol Cancer Ther. 2004 Dec;3(12):1693-9 PMID: 15634664
Article Info
Journal
European journal of pharmacology
Abbr.
Eur J Pharmacol
ISSN
1879-0712
DOI
10.1016/j.ejphar.2009.09.067
Email
hossein.borghaei@fccc.edu
Published
2009-12-25
Epub
2009-00-20
Pages
41-54
Language
English
Region
Netherlands
NLM ID
1254354
PMCID
PMC2783916
Subset
IM
Grants
NCI NIH HHS · P30 CA006927-47S5 · United States
NCI NIH HHS · R01 CA083859-08 · United States
NCI NIH HHS · R56 CA100226-06A1 · United States
NCI NIH HHS · R01 CA083859 · United States
NCI NIH HHS · CA06927 · United States
NCI NIH HHS · R56 CA100226 · United States
NCI NIH HHS · CA100226 · United States
NCI NIH HHS · CA083859 · United States
NCI NIH HHS · R01 CA100226 · United States
NCI NIH HHS · P30 CA006927 · United States
External Links
PubMed source DOI: 10.1016/j.ejphar.2009.09.067 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2